Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny power plants in cells may weaken bones, new study hints

NCT ID NCT05483738

Knowledge-focused Sponsor: Aalborg University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how problems with mitochondria—the tiny power plants inside cells—might affect bone health. Researchers will compare 30 people with certain genetic changes that cause mitochondrial dysfunction to healthy volunteers. They will take blood, bone marrow, and bone samples to measure how bone cells use energy and how bone structure looks. The goal is to better understand the link between mitochondrial disease and bone remodeling disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how mitochondrial problems affect bone health, pointing toward future treatments for bone disorders.
What could go wrong
This is a small, early-stage observational study with only 30 participants. It aims to understand biology, not test a treatment, so direct benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - cases: * Genetic diagnosis with: MT-TL1 m.3243A\>G, or POLG variant, het or TWNK variant, het, \> 18 years * Signed informed consent Inclusion Criteria - controls: * Healthy subjects matched on age and gender \> 18 years * Signed informed consent Exclusion Criteria: * Renal (creatinine \> 90 µmol/l) * Liver dysfunction (AST \> 3 times the upper limit) * Medical treatment influencing bone metabolism (oral corticosteroid \<12 weeks, anti-osteoporosis treatment, sex steroids, anti-convulsants) * Pregnancy * Excessive consumption of alcohol * Treatment with anticoagulants * Pre-existing coagulopathy * Allergy to lidocaine, morphine or diazepam.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone remodeling disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone remodeling disease inborn mitochondrial metabolism disorder MELAS syndrome caused by mutation in MTTL1 mitochondrial disease mitochondrial DNA depletion syndrome 7 (hepatocerebral type)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone remodeling disorder Mitochondrial diseases

Contacts and locations

Locations

  • Dept. of Clinical Genetics

    Aalborg, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.